Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Fineline Cube Apr 21, 2026
Company Deals Digital

AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management

Fineline Cube Apr 21, 2026
Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status

Fineline Cube Apr 21, 2026
Company Drug

Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance

Fineline Cube Apr 21, 2026
Company Drug

Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials

Fineline Cube Nov 19, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NMPA’s CDE Issues Guidelines for Leveraging Real-World Data in Drug Regulation

Fineline Cube Nov 19, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...

Company Deals

Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502

Fineline Cube Nov 19, 2024

Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered...

Company Deals

Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer

Fineline Cube Nov 19, 2024

US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with...

Company Drug

Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study

Fineline Cube Nov 19, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...

Company Drug

TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study

Fineline Cube Nov 19, 2024

China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...

Company Drug

Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population

Fineline Cube Nov 19, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has...

Company Drug

Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China

Fineline Cube Nov 19, 2024

China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...

Company Deals

VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC

Fineline Cube Nov 19, 2024

Shanghai-based biotech company VelaVigo, specializing in bispecific/multi-specific antibodies and antibody drug conjugates (ADCs), has announced...

Company Deals

Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments

Fineline Cube Nov 19, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered...

Company Deals

Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China

Fineline Cube Nov 18, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Deals

Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336

Fineline Cube Nov 18, 2024

Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...

Company Drug

CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine

Fineline Cube Nov 18, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...

Company Deals

Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments

Fineline Cube Nov 18, 2024

Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...

Company Deals

NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology

Fineline Cube Nov 18, 2024

China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...

Company Deals

Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design

Fineline Cube Nov 18, 2024

Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion...

Company Drug

EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment

Fineline Cube Nov 18, 2024

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...

Company Drug

EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC

Fineline Cube Nov 18, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition

Fineline Cube Nov 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced...

Company Drug

Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases

Fineline Cube Nov 18, 2024

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...

Posts pagination

1 … 253 254 255 … 654

Recent updates

  • Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma
  • CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status
  • AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management
  • UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim
  • Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Company Drug

CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status

Company Deals Digital

AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management

Company Legal / IP Medical Device

UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.